Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Advanced Esophageal Squamous Cell Carcinoma
NCT03170310Phase 2Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Feb 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Henan Cancer Hospital. Primary endpoint: Progression Free Survival at 24 months. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03170310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03170310.